Micap UK micro encapsulation logo

News and articles

18th November 2005g New
Notice of Annual General Meeting and Extraordinary General Meeting - Capital Reduction - Capital Reorganisation

26th September 2005g New
Yeast 'up the nose' may save diabetic patients from the pain of injections

21st September 2005
Preliminary announcement for the twelve months to 31st March 2005

5th May 2005gg          
Newsletter Issue 2.3
23rd February 2005gg
Acquisition of Rendel & Scherer GbR ("R&S") for up to €1.0 million
 
23rd Augustg2004
Micap announces option agreement with BioProgress plc
17th August 2004
Skyepharma exercises option under agreement with micap

8th July 2004
Commencement of clinical
trials into MRSA

1st June 2004
Global launch by flavour

10th May 2004
Micap in joint agreement with Fertin
1st March 2004
Grant of licence for
pharmaceutical applications
20th January 20th 2004
Research update
2003 August 7th
Micap plc floats on AIM!
2003 July 24th
Intention to float on AIM
2003 June 1st
Flavour License Deal

2003 May 1st
SMART Award

2003 January 13th
Skye Pharma Investment

Press Release 26-09-2005

New Research:
Yeast ‘Up The Nose’ may save diabetic patients
                         from the pain of injection

Traditionally yeast has been used for making beer and bread. But researchers at Leeds University have found that it may be crucial in helping diabetic patients to deliver insulin – up the nose.

The preliminary research, reported at the British Pharmaceutical Conference today ( 26 th September ), found that specially treated yeast might help to deliver insulin through the nasal mucosa ( the layer of tissue lining the nose ). A nasal spray formulation would avoid the need for regular insulin injections for patients with diabetes.

Getting insulin into the bloodstream via the nasal mucosa is tricky. The molecule is too large to readily penetrate through the nasal tissue and some sort of penetration enhancer is needed.

Emily Fuller, from the School of Biochemistry and Microbiology at Leeds University , has been investigating the properties of yeast as a penetration enhancer. She explained: “Transport of large molecules, such as insulin, through the nasal mucosa is limited because of the tight structure of the cell layer which forms an impenetrable barrier. Penetration enhancers work by opening this barrier.”

Ms Fuller says: “Our laboratory results show that yeast cells successfully enhanced the penetration of insulin. Yeast is beneficial as a penetration enhancer because it shows reversible effects, is non-toxic and is readily available.”

Yeast has structural similarities to chitosan, an established penetration enhancer, but the mechanism of how yeast opens the tight junctions between nasal cells is not yet clear. Further studies to investigate this are underway.

Another strand of the Leeds research is to investigate the use of yeast as a drug delivery system. The idea here is that it might be possible to encapsulate active drugs inside the yeast cell, to protect the drugs until they get to their site of action as well as acting as a penetration enhancer.

Ms Fuller’s research is part funded by Micap Plc, a company that specialises in microencapsulation and delivery of active agents using yeast cells, and the Biotechnology and Biological Sciences Research Council. (BBSRC)

Click below to download the PDF version of a poster that was displayed recently at the British Pharmaceutical Conference

Title
Date
File Type
File Size
 
       
26-09-05
0.51MB
           



 

© 2004. All rights reserved